论文部分内容阅读
目的分析探讨儿科呼吸系统反复感染的治疗方法以及治疗效果。方法选取了60例呼吸系统反复感染的患儿,根据治疗方法的不同分为试验组(30例)和对照组(30例)。对照组患者被给予吸氧雾化联合抗感染治疗,在对照组的基础上,试验组患者被给予口服匹多莫德颗粒剂治疗。记录两组患者治疗后的平均感染次数、平均感染时间、治疗有效率及患者满意度,以总结治疗儿科呼吸系统反复感染的有效方法。结果护理组的总有效率(100.00%)显著优于对照组(80.00%);护理组的平均感染次数(1.98±0.33)次显著优于对照组(4.65±1.21)次;护理组的平均感染时间(3.65±1.01)d显著优于对照组(7.98±0.93)d;护理组的患者满意度(100.00%)显著优于对照组(90.00%);两组差异均具有统计学意义(P<0.05)。结论吸氧+雾化+抗感染治疗联合口服匹多莫德颗粒剂在儿科呼吸系统的反复感染的治疗中疗效显著,降低再感染次数和程度,患者满意度高,值得临床的推广与应用。
Objective To analyze and discuss the treatment and treatment of recurrent respiratory infections in children. Methods Sixty children with recurrent respiratory infections were selected and divided into experimental group (30 cases) and control group (30 cases) according to different treatment methods. Patients in the control group were given inhalation aerosol combined with anti-infective therapy. On the basis of the control group, patients in the test group were given oral pidotimod granules. Record the average number of infections, average infection time, treatment efficiency and patient satisfaction after treatment in both groups to summarize the effective treatment of recurrent respiratory infections in children. Results The total effective rate (100.00%) in the nursing group was significantly better than that in the control group (80.00%). The average number of infections in the nursing group (1.98 ± 0.33) was significantly better than that in the control group (4.65 ± 1.21) (3.65 ± 1.01) d was significantly better than that of the control group (7.98 ± 0.93) d. The satisfaction of the patients in the nursing group (100.00%) was significantly better than that of the control group (90.00%), the differences between the two groups were statistically significant (P < 0.05). Conclusion Oxygen inhalation combined with atomization and anti-infection treatment combined with oral pidotimod granules have a significant effect in the treatment of recurrent infections in pediatric respiratory system, reduce the frequency and extent of reinfection, patients with high satisfaction, worthy of clinical promotion and application.